Original Articles: Clinical ResearchClinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experienceMazzini, Cinziaa,,b; Pieretti, Giuliaa,,b; Vicini, Giulioa,,b; Nicolosi, Cristinaa,,b; Scoccianti, Silviac; Pertici, Maurizioc; Greto, Danielac; Desideri, Isaccoc; Bordi, Lorenzod; Pecchioli, Guidod; Virgili, Giannib,,eAuthor Information aUnit of Ocular Oncology, Neuromuscular and Sense Organs Department bEye Clinic, Neuromuscular and Sense Organs Department cRadiotherapy Unit, Department of Oncology dNeurosurgery Unit, Neuromuscular and Sense Organs Department, Careggi University Hospital eUniversity of Florence, Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Florence, Italy Received 26 March 2020 Accepted 27 June 2020 Correspondence to Giulio Vicini, MD, Eye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy, Tel: +39 0557946975; e-mail: [email protected] Melanoma Research: February 2021 - Volume 31 - Issue 1 - p 38-48 doi: 10.1097/CMR.0000000000000689 Buy Metrics Abstract We retrospectively analyzed data from records of 48 patients (48 eyes) treated with gamma-knife (n = 18) or Ruthenium-106 brachytherapy (n = 30) for uveal melanoma, in our Ocular Oncology Unit between December 2013 and September 2019, with the aim to evaluate treatment outcomes, and incidence and risk factors for secondary glaucoma. Patients demographics and tumor characteristics at diagnosis were recorded. Follow-up data were collected regarding local tumor control, treatment complications, enucleation need, metastases occurrence and survival status. The median follow-up period was 33.7 months in the gamma-knife group and 26.2 months in the brachytherapy group. The mean tumor thickness, the largest basal diameter and the tumor volume were significantly higher in the gamma-knife group than in the brachytherapy group. The local tumor control rate was 100% in the brachytherapy group and 77.8% in the gamma-knife group. In the gamma-knife group, six patients were enucleated, no patient treated with brachytherapy underwent enucleation. The overall survival rate was 96.7% in the brachytherapy group and 94.44% in the gamma-knife group. Secondary glaucoma occurred in 10 patients after gamma-knife and in one patient after brachytherapy: it should be emphasized that larger lesions were treated with gamma-knife, whereas smaller tumors were selected for brachytherapy. We found a significative correlation of tumor thickness (P value = 0.043) and volume (P value = 0.040) with secondary glaucoma occurrence after gamma-knife treatment. Moreover, secondary glaucoma significantly correlated with radiation retinopathy in the gamma-knife group (P value = 0.009). This study shows preliminary clinical results that could be useful for further studies with more patients and longer follow-up. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.